Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery. (August 2015)

• Record Type: Journal Article
• Authors: Schmidt, Matthias C.; Uhrhan, Klara; Fischer, Thomas; Schmitz, Stephan; Markiefka, Birgid; Drzezga, Alexander; Stippel, Dirk
• Is Part Of: Clinical nuclear medicine. Volume 40:Number 8(2015)
• Publication Date: 2015-08
• Subjects: neuroendocrine carcinoma -- liver metastases -- 68Ga-DOTATATE PET/CT -- 177Lu-DOTATATE -- peptide receptor radionuclide therapy; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000000805
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 48-year-old man presenting with upper abdominal pain was diagnosed with neuroendocrine tumor after biopsy of a paragastric mass with multiple liver metastases. 68 Ga-DOTATATE PET/CT showed intense uptake in the paragastric tumor and in multiple liver metastases not allowing primary surgery. Two cycles with cumulative 14.6 GBq 177 Lu-DOTATATE were given resulting in a considerable improvement. Subsequent surgery resulted in a complete remission as demonstrated by 68 Ga-DOTATATE PET/CT. Usually, peptide receptor radionuclide (PRRT) therapy is considered a palliative treatment. Few patients demonstrate a very favorable response allowing resection of the primary tumor after downstaging metastatic disease burden.